Novotech
Novotech is a privately held, full-service clinical research organization (CRO) serving biotechnology and small-to-mid-sized pharmaceutical companies globally, with 2,300+ employees across Asia-Pacific, North America, and Europe, delivering clinical trial management across all phases and therapeutic areas.
- Company typePrivate
- Founded1992
- HeadquartersSydney, Australia
- Headcount1,001–5,000
- GTM typeB2B
- OfferingServices
What Novotech does
Novotech is a privately held, full-service clinical research organization (CRO) founded in 1992, originally headquartered in Sydney, Australia, and repositioned with a new global headquarters in Singapore as of January 2026 under incoming CEO Dr. Anand Tharmaratnam. The company delivers integrated biotech clinical trial services across all phases (Phase I-IV) and therapeutic areas — including oncology, liver disease, infectious diseases and vaccines, orphan/rare diseases, and pharmacometrics — to biotechnology companies and small-to-mid-sized pharmaceutical firms globally. Novotech operates 30+ offices across Asia-Pacific, North America, and Europe with over 2,300 full-time employees, maintaining a network of 5,000+ trial sites, 4,950+ investigators, and a track record of 4,450+ completed trials across 50+ countries with 60+ drugs brought to market.
The company's service portfolio spans medical and regulatory consulting, clinical operations and project management, biometrics and data management, real-world data analytics, bioanalytical laboratory services, and a flexible clinical staffing platform called FLEX, complemented by wholly owned subsidiaries including Acrostar (a Site Management Organization founded in 2013) and BioDesk (regulatory consulting). Novotech holds a distinctive regulatory position as the operator of Australia's first privately owned commercial Institutional Biosafety Committee certified by the Office of the Gene Technology Regulator (OGTR), enabling GMO clinical trial certification, and leverages Australia's 43.5% R&D cash refund scheme to attract early-phase studies. In February 2026, the company entered a multi-trial licensing agreement with ObvioHealth to deploy the ObvioGo digital trial platform (eConsent, ePRO/eCOA, remote/hybrid assessments) across its programs.
Novotech monetizes through project-based, quote-driven professional services contracts with biotech and pharma sponsors, with pricing varying by trial complexity, phase, therapeutic area, and geography. The company is majority-backed by TPG Capital Asia (via its Asia VIII fund), with Singapore sovereign wealth funds GIC and Temasek taking stakes in March 2025 at a valuation exceeding A$3 billion, following a US$760M financing in January 2022. The go-to-market is direct enterprise sales with relationship-based engagement across APAC, Europe, and North America, supported by industry-leading recognition including 19 consecutive years of Frost & Sullivan CRO Company of the Year awards.
Novotech firmographics
Firmographics- Name
- Novotech
- Legal name
- Novotech Health Holdings
- Website
- https://novotech-cro.com
- Company type
- Private
- Founded year
- 1992
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Novotech is a privately held, full-service clinical research organization (CRO) serving biotechnology and small-to-mid-sized pharmaceutical companies globally, with 2,300+ employees across Asia-Pacific, North America, and Europe, delivering clinical trial management across all phases and therapeutic areas.
- Ownership category
- akta.pro rank
Novotech industry classification
Industry- Product category
- Clinical Research Organization (CRO) Services
- NAICS
- Scientific Research and Development Services (5417)
- SIC
- Services-Engineering, Accounting, Research, Management (8700)
- akta.pro primary industry
- Clinical CROs (Phase I–IV) (HLAGAAAA)
- akta.pro secondary industries
- Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL), Clinical Site Start-Up & Activation (Regulatory/Ethics/Contracts) (HLAGACAC), Clinical Data Management, Biostatistics & Statistical Programming CROs (HLAGAAAF)
Keywords
Where Novotech is headquartered
LocationHeadquarters
- HQ city
- Sydney
- HQ country
- Australia
- HQ region
- Oceania
Offices3 records
Markets served
Novotech business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales
Revenue model
- Clinical Research Organization Services: Project-based CRO services providing full-service clinical trial management across Phase I to Phase IV, including clinical operations, project management, site management, biometrics, data management, regulatory affairs, medical monitoring, safety services, and central lab services. Revenue generated through individual project contracts with biotech and pharmaceutical sponsors.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels7 records
Novotech product offering
Product offeringCore offering
Novotech is a globally recognized full-service clinical research organization (CRO) that provides integrated clinical trial services for biotech and small-to-mid-sized pharmaceutical companies across all phases (Phase I to Phase IV) and therapeutic areas. Service offerings span clinical operations, project management, biometrics, data management, regulatory affairs, medical monitoring, safety/pharmacovigilance, central lab services, site management (via Acrostar SMO), regulatory consulting (via BioDesk), and clinical staffing (via FLEX), delivered through 30+ offices across Asia-Pacific, North America and Europe.
Product overview
Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company that guides biotech and small-to-mid-sized pharmaceutical companies through all phases of drug development. The company operates across Asia-Pacific, North America, and Europe through 30+ offices, with partnerships spanning 5,000+ trial sites and 4,950+ investigators. The portfolio is organized around a core set of service modules — Medical and Regulatory Consulting, Patient Recruitment and Site Selection, Early Phase Trials in Australia, Clinical Operations and Project Management, Biometrics and Data Management, Real World Data, Laboratory Services, and FLEX staffing solutions — supplemented by a specialized SMO division (Acrostar) and a regulatory consulting subsidiary (BioDesk). Novotech's therapeutic expertise spans Oncology, Pharmacometrics, Drug Development Consulting, GMO Solutions, Liver Disease, Infectious Diseases and Vaccines, and Orphan and Rare Diseases. The company has conducted 4,450+ clinical trials across 50+ countries, bringing 60+ drugs to market. Recent strategic expansions include radiopharmaceutical trials and partnerships with companies like Tune Therapeutics and Biostar. Notable acquisitions include EastHORN (European CRO, 2023) and NCGS (US CRO, 2022), with a US$760M financing round completed in January 2022 valuing the company at ~US$3 billion.
Differentiator
Problem solved
Functional benefit
Products and services
- Medical and Regulatory Consulting Full range of pre-clinical support, regulatory affairs, medical, and pharmacovigilance consulting services to guide biotech companies through clinical development and approval processes.
- Patient Recruitment and Site Selection Uses years of experience, in-country knowledge, and real-world big data to identify and propose the best-performing sites for clinical trials, accelerating enrollment timelines.
- Early Phase Trials in Australia Australia-based early-phase clinical trial services leveraging the country's streamlined regulatory pathway and 43.5% R&D cash refund scheme, enabling faster study initiation and cost savings.
- Clinical Operations and Project Management Streamlined and integrated clinical trial services delivered by a dedicated team of professionals covering project management, clinical monitoring, and patient recruitment across all trial phases.
- Acrostar SMO Division Site Management Organization (SMO) services operating across Asia-Pacific including China, Taiwan, and South Korea, providing clinical trial site management services for sponsors.
- Biometrics and Data Management Asia-Pacific internal biometrics and statistical programming team delivering biostatistics services including statistical planning, analysis, regulatory submission, and reporting for clinical trials.
- Real World Data Service leveraging large-scale observational real-world data to support site selection, patient stratification, adaptive trial design, and evidence generation across clinical programs.
- Laboratory Services Bioanalytical services assisting customers at every stage of molecule development, covering preclinical through clinical phases with comprehensive laboratory support.
- FLEX Clinical Staffing Solution Clinical staffing solution offering a predictable budget plan for ongoing clinical pipelines and flexibility to scale up or down, integrating talent, processes, technology, and information infrastructure for sponsors.
- Oncology CRO Services Global oncology-focused clinical research services for biotechnology companies, supporting trial design, site selection, and execution across solid tumors and hematologic malignancies.
- Liver Disease CRO Services Specialized liver disease clinical trial services covering Hepatitis B and C, HCC, NASH, NAFLD, and liver transplantation; over 200 liver disease clinical trials conducted over 25 years.
- Infectious Diseases and Vaccines CRO Services Comprehensive CRO services for infectious diseases and vaccine trials, including feasibility assessments, protocol design, and patient recruitment strategies (adult and pediatric) across HIV, influenza, Hepatitis B and C, malaria, CMV, RSV, and COVID-19.
- Orphan and Rare Disease CRO Services Rare disease clinical research services with specialized expertise in patient recruitment and registry access; over 20 trials conducted across indications including acromegaly, cystic fibrosis, DMD, Gaucher disease, and PNH.
- Pharmacometric Services Pharmacometric team assisting across all clinical study phases and designs including first-in-human, single ascending dose, multiple ascending dose, drug-drug interaction, food effect, and special population studies.
- Drug Development Consulting Full-service global product development and strategic regulatory group providing comprehensive lab-to-launch program development services including clinical and regulatory strategy.
- GMO Solutions Service enabling sponsors to obtain and retain certification for clinical trials using genetically modified organisms (GMOs) in Australia via Novotech's privately-owned commercial Institutional Biosafety Committee (IBC), certified by OGTR.
- BioDesk Regulatory Consulting Wholly-owned clinical and regulatory consulting subsidiary providing biotech companies with regulatory expert support for clinical and drug development planning, GMP product preparation, GLP toxicology coordination, and IND/NDA submissions to FDA and EMA.
Quantifiable outcome
- 4,450+ clinical trials completed across 50+ countries
- +4 more outcomes
Companies that use Novotech
Customer profileNamed customers5 records
Segments2 records
Ideal customer profiles2 records
Novotech technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability2 records
Feature5 records
Novotech partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered strategic and core.
- Marvel Biosciences Corp.strategicMarvel Biosciences selected Novotech as CRO for its Phase I clinical trial of MB-204, a neuroactive adenosine A2A antagonist for neurodevelopmental disorders including Rett syndrome, Fragile X syndrome, autism, and depression. Trial conducted in Australia leveraging favorable regulatory environment.
- ObvioHealthstrategicNovotech entered a strategic multi-trial licensing agreement with ObvioHealth to license the ObvioGo platform across multiple clinical trials. The enterprise platform combines eConsent, ePRO/eCOA, and remote/hybrid assessments, enabling Novotech teams to reuse standardized digital workflows.
- Primmune TherapeuticsstrategicNovotech serves as CRO for Primmune's Phase 2 neoadjuvant efficacy study (PRTX007-003) of PRTX007, a novel orally administered TLR7 agonist immunotherapy for solid tumors. Study conducted entirely in Australia.
- Tune TherapeuticscoreStrategic partnership focusing on a groundbreaking clinical trial program advancing epigenome editing therapy for chronic hepatitis B (CHB). The partnership combines Novotech's regulatory, operational, and clinical expertise with Tune's innovative TEMPO gene调节 platform. Awarded Citeline CRO Partnership of the Year 2025.
- Kyungpook National University HospitalstrategicPartnership to strengthen clinical trial capabilities in Korea, enhancing Novotech's presence and operational capacity in the Korean market.
- Beijing Biostar PharmaceuticalsstrategicStrategic partnership established following Biostar's successful listing on Hong Kong Stock Exchange. Collaboration aims to accelerate clinical research and support Biostar's development of innovative oncology drugs, leveraging both companies' expertise to expand international presence.
- EastHORN Clinical ServicescoreNovotech acquired EastHORN, a European CRO headquartered in Poland, as part of its global expansion program. The acquisition enhanced Novotech's ability to provide in-country clinical development services across Europe, North America, and Asia-Pacific, integrating EastHORN's European expertise.
- NCGScoreNovotech acquired US CRO NCGS to expand global clinical trial capabilities, particularly supporting biotechs in the US and APAC regions. The move integrated US expertise and infrastructure for later-phase global studies.
Scale indicators10 records
Recent moves8 records
Expansion highlights6 records
Novotech competitors and assessment
Company assessmentBroad incumbents
- IQVIA: The world's largest CRO and a Novotech competitor for global biotech and pharma trial work. Novotech's incoming CEO spent 23 years at IQVIA, underscoring IQVIA as the standard against which Novotech benchmarks scale and preferred-provider positioning.
- Fortrea (formerly Labcorp Drug Development / Covance): Large global CRO spun out of Labcorp with end-to-end clinical development plus central lab services. Overlaps with Novotech on clinical operations, biometrics, and central lab work, particularly for biotech sponsors seeking late-phase global capacity.
- WuXi AppTec: Asia-based CRO/CDMO offering clinical and preclinical services alongside broader drug development capabilities. Overlaps with Novotech's clinical operations in China and APAC, and is a comparable regional alternative for biotech sponsors.
- Charles River Laboratories: Large CRO with a strong preclinical and discovery franchise plus growing clinical services. Comparable to Novotech on the early-phase/biopharma-services side, particularly for biotech sponsors seeking integrated discovery-to-clinical support.
Direct peers
- ICON plc: Top-tier global CRO formed via the PRA Health Sciences merger, with broad Phase I–IV capabilities and a strong biotech sponsor book. Directly competes with Novotech for global biotech trial outsourcing and biotech preferred-provider mandates.
- Tigermed (Hangzhou Tigermed): China-headquartered full-service CRO with growing international presence. Closest APAC-headquartered peer to Novotech, competing for cross-border biotech trials and providing a direct benchmark on China-based clinical operations.
- Parexel International: PE-owned global CRO with deep biotech sponsor relationships and full Phase I–IV services. Competes head-to-head with Novotech for mid-sized biotech trial outsourcing and represents a comparable ownership archetype under PE ownership.
- Medpace: Mid-sized global CRO with a biotech-focused business model emphasizing operational excellence and high-quality data. Closest comparable in terms of sponsor-segment targeting, with disclosed financials that benchmark Novotech's organic growth profile.
- Syneos Health: Clinical and commercial services provider serving biotech and pharma sponsors globally. Overlaps with Novotech on full-service clinical operations and is a directly comparable full-service peer for biotech outsourcing decisions.
Emerging players
- Worldwide Clinical Trials: Mid-sized global CRO focused on complex clinical trials across multiple therapeutic areas. Comparable to Novotech in size and biotech-segment positioning, providing a useful mid-tier benchmark for trial volume and therapeutic mix.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Novotech social profiles
Digital presenceNovotech compliance and trust
Trust signalCompliance2 records
Novotech financial estimates
Financial estimateRevenue estimate
Valuation estimate
Novotech leadership team
Management profileNumber of profiles
Profiles9 records
Novotech subsidiaries and ownership
Company hierarchySubsidiaries4 records
Novotech funding detail
Funding detailFunding overview
Funding rounds5 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Novotech M&A and investment
M&A and investmentM&A5 records
Investments3 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Novotech
What does Novotech do?
Novotech is a globally recognized full-service clinical research organization (CRO) that provides integrated clinical trial services for biotech and small-to-mid-sized pharmaceutical companies across all phases (Phase I to Phase IV) and therapeutic areas. Service offerings span clinical operations, project management, biometrics, data management, regulatory affairs, medical monitoring, safety/pharmacovigilance, central lab services, site management (via Acrostar SMO), regulatory consulting (via BioDesk), and clinical staffing (via FLEX), delivered through 30+ offices across Asia-Pacific, North America and Europe.
Is Novotech a public or private company?
Novotech is a private company. It is classified as private equity controlled and is currently operating.
When was Novotech founded?
Novotech was founded in 1992. It employs 1,001 to 5,000 people.
Where is Novotech based?
Novotech is headquartered in Sydney, Australia, in the Oceania region.
How does Novotech make money?
One revenue line is on record: clinical Research Organization Services.
Who are Novotech's main competitors?
Broad incumbents on record are IQVIA, Fortrea (formerly Labcorp Drug Development / Covance), WuXi AppTec and Charles River Laboratories. Direct peers are ICON plc, Tigermed (Hangzhou Tigermed), Parexel International, Medpace and Syneos Health. Worldwide Clinical Trials is listed as an emerging player.
Does Novotech have an API?
No public API is recorded for Novotech.
What industry is Novotech in?
Novotech's product category is Clinical Research Organization (CRO) Services. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease). Its NAICS code is 5417 and its SIC code is 8700.